The current state and future perspectives of radiotherapy for cervical cancer

被引:0
|
作者
Yamada, Takehiro [1 ,4 ]
Kawamura, Mariko [1 ]
Oie, Yumi [1 ]
Kozai, Yuka [1 ]
Okumura, Masayuki [1 ]
Nagai, Naoya [1 ]
Yanagi, Yusuke [1 ,2 ]
Nimura, Kenta [1 ,3 ]
Ishihara, Shunichi [1 ]
Naganawa, Shinji [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Radiol, Nagoya, Japan
[2] Toyota Mem Hosp, Dept Radiol, Toyota, Japan
[3] Tosei Gen Hosp, Dept Radiol, Seto, Japan
[4] 65 Tsurumai Cho,Showa Ku, Nagoya 4668560, Japan
关键词
artificial intelligence; cervical cancer; future perspectives of radiotherapy; radiotherapy; technological innovation; GUIDED ADAPTIVE BRACHYTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; RATE INTRACAVITARY BRACHYTHERAPY; CARBON-ION RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; CONCURRENT CHEMORADIOTHERAPY; CLINICAL-OUTCOMES; BEAM RADIOTHERAPY; PROTON THERAPY; PHASE-II;
D O I
10.1111/jog.15998
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Radiotherapy is an effective treatment method for cervical cancer and is typically administered as external beam radiotherapy followed by intracavitary brachytherapy. In Japan, center shielding is used in external beam radiotherapy to shorten treatment time and reduce the doses delivered to the rectum or bladder. However, it has several challenges, such as uncertainties in calculating the cumulative dose. Recently, external beam radiotherapy has been increasingly performed with intensity-modulated radiotherapy, which reduces doses to the rectum or bladder without center shielding. In highly conformal radiotherapy, uncertainties in treatment delivery, such as inter-fractional anatomical structure movements, affect treatment outcomes; therefore, image-guided radiotherapy is essential for appropriate and safe performance. Regarding intracavitary brachytherapy, the use of magnetic resonance imaging-based image-guided adaptive brachytherapy is becoming increasingly widespread because it allows dose escalation to the tumor and accurately evaluates the dose delivered to the surrounding normal organs. According to current evidence, a minimal dose of D90% of the high-risk clinical target volume is significantly relevant to local control. Further improvements in target coverage have been achieved with combined interstitial and intracavity brachytherapy for massive tumors with extensive parametrical involvement. Introducing artificial intelligence will enable faster and more accurate generation of brachytherapy plans. Charged-particle therapies have biological and dosimetric advantages, and current evidence has proven their effectiveness and safety in cervical cancer treatment. Recently, radiotherapy-related technologies have advanced dramatically. This review provides an overview of technological innovations and future perspectives in radiotherapy for cervical cancer.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 50 条
  • [21] Radiotherapy for Anal Cancer Intensity-Modulated Radiotherapy and Future Directions
    Castaneda, Serguei A.
    Romak, Lindsay B.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 26 (03) : 467 - +
  • [22] Tumor bleeding requiring intervention and the correlation with anemia in uterine cervical cancer for definitive radiotherapy
    Yanazume, Shintaro
    Karakida, Noriko
    Higashi, Ryutaro
    Fukuda, Mika
    Togami, Shinichi
    Kamio, Masaki
    Ota, Shunichiro
    Kobayashi, Hiroaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (10) : 892 - 899
  • [23] Cervical cancer therapy: current, future and anti-angiogensis targeted treatment
    Willmott, Lyndsay J.
    Monk, Bradley J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 895 - 903
  • [24] Radiotherapy of cervical cancer. Current developments and treatment standards for percutaneous radiotherapy and brachytherapy
    Schweizer, Claudia
    Strnad, Vratislav
    GYNAKOLOGIE, 2024, 57 (11): : 752 - 758
  • [25] Head and neck cancer: Current challenges and future perspectives
    Bhat, Gh. Rasool
    Hyole, Rosalie G.
    Li, Jiong
    ADVANCES IN CANCER RESEARCH, VOL 152, 2021, 152 : 67 - 102
  • [26] Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy
    Nakasone, Tadaharu
    Taira, Yusuke
    Shimoji, Yuko
    Arakaki, Yoshihisa
    Nakamoto, Tomoko
    Ooyama, Takuma
    Kudaka, Wataru
    Kaneshima, Itomi
    Nishihira, Kumiko
    Mekaru, Keiko
    Aoki, Yoichi
    IN VIVO, 2020, 34 (04): : 2173 - 2177
  • [27] Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer
    Aoshika, Tomomi
    Noda, Shin-ei
    Abe, Takanori
    Kumazaki, Yu
    Hirai, Ryuta
    Igari, Mitsunobu
    Saito, Satoshi
    Ryuno, Yasuhiro
    Iino, Misaki
    Takeda, Yuga
    Ohta, Tomohiro
    Watanabe, Jun
    Tsukahara, Keita
    Kato, Shingo
    ANTICANCER RESEARCH, 2024, 44 (04) : 1583 - 1589
  • [28] Pharmacotherapy for cervical cancer: current standard of care and new perspectives
    Ketch, Peter W.
    Zaharias, Rennan S.
    Leath, Charles A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (12) : 1591 - 1603
  • [29] Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives
    Marta, Gustavo Nader
    William, William N., Jr.
    Feher, Olavo
    Carvalho, Andre Lopes
    Kowalski, Luiz Paulo
    ORAL ONCOLOGY, 2015, 51 (12) : 1069 - 1075
  • [30] Target tailoring and proton beam therapy to reduce small bowel dose in cervical cancer radiotherapy
    de Boer, Peter
    van de Schoot, Agustinus J. A. J.
    Westerveld, Henrike
    Smit, Mark
    Buist, Marrije R.
    Bel, Arjan
    Rasch, Coen R. N.
    Stalpers, Lukas J. A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (03) : 255 - 263